Elsevier

Bone

Volume 51, Issue 2, August 2012, Pages 297-311
Bone

Review
Future therapeutics for osteoarthritis

https://doi.org/10.1016/j.bone.2011.10.008Get rights and content

Abstract

Osteoarthritis (OA) is a disease of the joints that affects several million individuals worldwide. This disease, which involves mainly the diarthrodial joints, is chronic and develops slowly over decades, making it very difficult to precisely identify the different etiological and risk factors that influence its onset. At present, most therapies for OA are symptomatic. This review will focus on new OA therapeutics in development that are directed toward pain relief as well as others with the potential to reduce or stop the progression of the disease (DMOADs).

This article is part of a Special Issue entitled “Osteoarthritis”.

Introduction

The most common form of joint disease, osteoarthritis (OA) represents a major cause of morbidity and disability, particularly in the second half of life. The burden of this disease has been steadily gaining importance in the last few decades with the aging of the world's population and has become by far the most common musculoskeletal disease, imposing enormous costs and challenges on the healthcare system. The increasing number of patients seeking treatment for this disease could very well cause a global financial “tsunami” in the near future.

Although important advances have been made in understanding the pathophysiological processes of OA, today's treatments still focus mainly on improving the symptoms. As the relationship between the pathology and pain of OA has become better defined, new concepts have emerged allowing the development of new therapeutic approaches that are likely to improve symptomatic treatment. The newer agents of this category will be reviewed.

Even though in the last few decades, finding a disease modifying OA drug (DMOAD) has remained elusive, research into the development of such new and innovative agents continues. The progress made in the understanding of the pathophysiology of OA and the identification of risk factors has guided DMOAD development programs toward promising therapeutic targets. These, as well as new drugs and agents aiming at stopping the disease progression, will be reviewed.

Of note, this review may not be fully comprehensive of all development programs as this field is advancing rapidly.

Osteoarthritis, which mainly affects the diarthrodial joints, is a chronic disease that develops progressively over decades, making it very difficult to precisely identify the different etiological and risk factors that influence the onset of the disease. In the majority of patients, the disease is considered to be idiopathic.

It is now well recognized that OA is not a single disease entity, but rather the common final stage of joint failure. Osteoarthritis of the knee is a heterogeneous chronic disease involving all the joint tissues and the initial stages can be triggered by numerous causes and/or factors. Hence, it would seem logical that the disease be divided into subgroups, some of which may have a more biomechanical, biochemical, inflammatory or genetic signature. All these subgroups may eventually converge into a common phenotype.

It is well known that OA structural changes are mediated by a multitude of complex autocrine and paracrine anabolic and catabolic factors that act upon diverse cells from articular tissues. Studies have revealed that there is some continuity between the subchondral bone and cartilage as well as between the synovial membrane and cartilage, suggesting cross-talk between these tissues. However, the exact sequence of pathological events in OA remains unclear, as the temporal relationship between cartilage erosion, chronic synovial inflammation and subchondral bone remodeling has yet to be determined.

Section snippets

Symptomatic drugs for osteoarthritis (Table 1)

The most common treatment prescribed for OA is for symptomatic relief, to control the pain and improve joint function. Pain in OA is difficult to classify, as the factors contributing to its genesis such as inflammation and neuropathic and/or nociceptive pain components have yet to be fully identified. The specific sources of OA pain within the joint have also remained elusive and are likely to be multiple, including tissues of the joint such as the subchondral bone, the synovium, and the soft

Disease modifying osteoarthritis drugs (DMOADs)

The ultimate vision for the treatment of OA has been to find agents that can reduce or stop the progression of the disease. Thus far no such treatment has been approved by regulatory authorities as meeting the appropriate guidelines and criteria. However, a number of agents present several interesting properties including an extremely low incidence of side effects, a carryover effect of several weeks, and some have an additive effect with NSAIDs. These include chondroitin sulfate [30], [31],

Targeting synovial membrane inflammation

In OA, the role of synovial inflammation in the pathophysiology of OA is now widely accepted. Synovitis has been considered secondary to the cartilage changes yet findings indicate that synovial inflammation could be a component of the early events leading to the clinical stage of OA. Synovial inflammation leads to the production and release of pro-inflammatory cytokines and several other inflammatory mediators. Some of these factors, including the pro-inflammatory cytokines, diffuse through

Targeting subchondral bone remodeling

Emerging evidence suggests that changes in subchondral bone are closely involved in the disease progression. Data even indicate that the subchondral bone alterations may precede cartilage changes, and this tissue is suggested to be the site of the causally most significant pathophysiological events occurring in the cartilage. It is now believed that very early in the OA process, biological and morphological disturbances occur at the subchondral bone level that play a role in modulating

DMOAD clinical research

Based on experience from the conduct of DMOAD trials in the last decades, there is no doubt that such studies present major challenges. Firstly, protocols for these trials were highly variable from one study to another. For example, inclusion/exclusion criteria including disease severity, demographics, risk factors, and structural changes differed quite significantly among the studies, having an obvious impact on the results and making it very difficult to analyze and compare the results of a

Conclusion

A number of major hurdles are responsible for the almost idle effort to develop new DMOADs and these can be explained quite simply by three major factors that are intertwined: the slowly progressive loss of cartilage, the multifactorial nature of the disease, and the cyclical course with periods of active disease followed by remission. The unsatisfactory efficacy of currently available treatment options has led the current development efforts to focus mainly on pain drugs. This effort is

References (173)

  • M. Nishimura et al.

    Relationships between pain-related mediators and both synovitis and joint pain in patients with internal derangements and osteoarthritis of the temporomandibular joint

    Oral Surg Oral Med Oral Pathol Oral Radiol Endod

    (2002)
  • K. Kaneyama et al.

    Prognostic factors in arthrocentesis of the temporomandibular joint: comparison of bradykinin, leukotriene B4, prostaglandin E2, and substance P level in synovial fluid between successful and unsuccessful cases

    J Oral Maxillofac Surg

    (2007)
  • J.Y. Reginster et al.

    Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial

    Lancet

    (2001)
  • M. Kashiwagi et al.

    TIMP-3 is a potent inhibitor of aggrecanase-1 (ADAM-TS4) and aggrecanase-2 (ADAM-TS5)

    J Biol Chem

    (2001)
  • H. Zhao et al.

    Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 regulates pro-MMP-2 activation

    J Biol Chem

    (2004)
  • S. Wei et al.

    Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. In search of selective matrix metalloproteinase inhibitors

    J Biol Chem

    (2003)
  • M.E. Schnute et al.

    Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis

    Bioorg Med Chem Lett

    (2010)
  • P.S. Chockalingam et al.

    Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor

    Osteoarthritis Cartilage

    (2011)
  • M.G. Bursavich et al.

    5′-Phenyl-3′H-spiro[indoline-3,2′-[1,3,4]thiadiazol]-2-one inhibitors of ADAMTS-5 (aggrecanase-2)

    Bioorg Med Chem Lett

    (2007)
  • M.G. Bursavich et al.

    Synthesis and evaluation of aryl thioxothiazolidinone inhibitors of ADAMTS-5 (Aggrecanase-2)

    Bioorg Med Chem Lett

    (2007)
  • A.H. Bartlett et al.

    Molecular and cellular mechanisms of syndecans in tissue injury and inflammation

    Mol Cells

    (2007)
  • E.E. Moore et al.

    Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis

    Osteoarthritis Cartilage

    (2005)
  • R.A. Black et al.

    Generation of biologically active interleukin-1 beta by proteolytic cleavage of the inactive precursor

    J Biol Chem

    (1988)
  • G. Ku et al.

    Interleukin-1β converting enzyme inhibition blocks progression of the type II collagen-induced arthritis in mice

    Cytokine

    (1996)
  • K. Rudolphi et al.

    Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis

    Osteoarthritis Cartilage

    (2003)
  • D.E. Smith et al.

    The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action

    Immunity

    (2003)
  • E.H. Lin et al.

    Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial

    JAMA

    (2003)
  • S. Perrot et al.

    Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies

    Rheumatology (Oxford)

    (2008)
  • N.E. Lane et al.

    Tanezumab for the treatment of pain from osteoarthritis of the knee

    N Engl J Med

    (2010)
  • M.T. Brown et al.

    Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase 3 trial

    Ann Rheum Dis

    (2010)
  • M.T. Brown et al.

    A Phase 3 randomized, double-blind, placebo-controlled trial of analgesic efficacy and safety of tanezumab in patients with osteoarthritis of the hip

  • G.T. Whiteside et al.

    The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists

    Curr Med Chem

    (2007)
  • J. Guindon et al.

    Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain

    Br J Pharmacol

    (2008)
  • D. Richardson et al.

    Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis

    Arthritis Res Ther

    (2008)
  • L. Bunch et al.

    Subtype selective kainic acid receptor agonists: discovery and approaches to rational design

    Med Res Rev

    (2009)
  • K. Gavenis et al.

    Expression of ion channels of the TRP family in articular chondrocytes from osteoarthritic patients: changes between native and in vitro propagated chondrocytes

    Mol Cell Biochem

    (2009)
  • A.M. Valdes et al.

    The Ile585Val TRPV1 variant is involved in risk of painful knee osteoarthritis

    Ann Rheum Dis

    (2011)
  • R. Remadevi et al.

    Adlea (ALGRX-4975), an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief

    IDrugs

    (2008)
  • K.L. Melmon et al.

    The presence of a kinin in inflammatory synovial effusion from arthritides of varying etiologies

    Arthritis Rheum

    (1967)
  • V. Eisen

    Plasma kinins in synovial exudates

    Br J Exp Pathol

    (1970)
  • I.H. Song et al.

    Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI

    Ann Rheum Dis

    (2009)
  • S. Meini et al.

    Knee osteoarthritis: a role for bradykinin?

    Inflamm Res

    (2008)
  • B.A. Michel et al.

    Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial

    Arthritis Rheum

    (2005)
  • A. Kahan et al.

    Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial

    Arthritis Rheum

    (2009)
  • K. Pavelka et al.

    Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study

    Arch Intern Med

    (2002)
  • M. Dougados et al.

    Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip

    Arthritis Rheum

    (2001)
  • L.M. Wildi et al.

    Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI

    Ann Rheum Dis

    (2011)
  • H.J. Kerkhof et al.

    A genome-wide association study identifies an osteoarthritis susceptibility locus on chromosome 7q22

    Arthritis Rheum

    (2010)
  • K. Chapman et al.

    A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5′ UTR of GDF5 with osteoarthritis susceptibility

    Hum Mol Genet

    (2008)
  • Cited by (0)

    View full text